MedBen Rx Blog
Over 350 Brand-Name Drugs See a Price Increase in 2026
Pharmaceutical manufacturers are planning to raise list prices on at least 350 brand-name medications in the United States beginning in 2026, up from 250 drugs last year, according to new data from health care research firm 3 Axis Advisors. These increases reflect...
GLP-1 Spending Pressures States and Employers to Reassess Coverage
In recent months, a growing number of U.S. states have pulled back on covering GLP-1 medications for obesity under their Medicaid programs, even as the drugs remain broadly covered for diabetes. A recent KFF survey shows that while 16 state Medicaid programs still...
MedBen Rx Cuts Client’s First-Year Pharmacy Costs Nearly in Half
A new MedBen Rx client realized $1.19 million in combined plan and member savings in their first year – a 45.7% reduction, surpassing the $1.05 million projected savings. Per-member-per-month (PMPM) pharmacy costs tell the story: $233 under the previous PBM vs. just...
Prescription Patterns: How Employer Coverage Shapes Drug Utilization
A recent GoodRx list of the 20 most prescribed medications prompted MedBen Rx to take a closer look at how our own top prescriptions compare. Because GoodRx’s rankings largely reflect individuals who pay for medications out of pocket – rather than through...
Employers Take a Variety of Approaches to GLP-1 Coverage
A recent International Foundation of Employee Benefit Plans survey shows that while employers are open to covering GLP-1 drugs for diabetes, they’re far more hesitant to do so for weight loss. Over half of corporate and multiemployer/public plans cover GLP-1s for...
A Clear Path to Lower Pharmacy Costs
Across the country, more employers are moving away from traditional pharmacy benefit managers in favor of transparent solutions. MedBen Rx has been ahead of this trend for years, offering clients clarity and lower costs that others are only now beginning to...
Nutrigenomics: Personalizing Nutrition for a Healthier Workforce
Nutrigenomics is also known as "personalized nutrition" because it considers an individual's unique dietary needs as well as their health status and lifestyle. Nutrigenomic testing through MedBen Rx brings this emerging science into the workplace, offering your...
AMA Raises Concerns Over PBM Market Concentration
A new paper from the American Medical Association (AMA) has found that the pharmacy benefit manager (PBM) marketplace remains highly concentrated, with just a few major players controlling most of the activity. Many of these PBMs are vertically integrated with health...
Cutting Specialty Drug Costs Without Cutting Access
Specialty medications continue to drive a disproportionate share of prescription drug costs – often accounting for 60% or more of a pharmacy plan’s total spend. MedBen Rx’s Benefit Preservation helps plans manage these expenses without compromising...
Major PBMs Are Blocking Biosimilar Savings, but MedBen Rx Offers a Better Path
The advantages of biosimilars – clinically equivalent versions of high-price biologic drugs – have been known for years. But despite their growing availability, adoption remains slow... in no small part because major PBMs are stifling uptake. Fortunately,...
High-Value Formulary Helps Members Resist the Pharma Ad Blitz
Pharmaceutical advertising hit a record high in 2024, with the top 10 drugs accounting for $3.3 billion in ad spending – up nearly 20% from the previous year. With more campaigns directly targeting consumers, MedBen Rx’s high-value formulary educates members about...
Reclaim Your Prescription Drug Spend with Smarter Pharmacy Benefits
The 2025 Milliman Medical Index confirms what many employers are seeing firsthand: prescription drug costs are rising faster than any other health care expense, with a 9.7% increase over the past year. To help employers reclaim their drug spend, MedBen Rx offers a...